Carboplatin therapy in advanced endometrial cancer

Jb, Green; Green, S; Ds, Alberts; O'Toole, R; Ea, Surwit; Noltimier, JW

doi:10.1016/0020-7292(91)90588-v

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Feuer et al (1987) and Rose et al (1992) reported that postsurgical radiotherapy was effective for microscopic node metastases of endometrial cancer, whereas it had no favourable effect on macroscopic node metastases. On the other hand, the response Received 22 October 1996Revised 24 December 1996 Accepted 18 January 1997 Correspondence to: T Onda, Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113, Japan rate of chemotherapy for endometrial cancer has been reported to be 30-57% (Seski et al, 1982;Hancock et al, 1986;Green et al, 1990), which is still lower than that for ovarian cancer. Hence, the rational treatment of endometrial cancer with positive lymph nodes is not clarified.…”

mentioning

confidence: 99%

Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy

Onda

Yoshikawa²,

Mizutani³

et al. 1997

Br J Cancer

164

View full text Add to dashboard Cite

SummaryWe assessed the therapeutic significance of systematic aortic and pelvic lymphadenectomy followed by adjuvant therapy in nodepositive endometrial carcinoma. Among 173 stage lll patients, 30 (17%) had positive nodes: ten in the pelvic region alone (group P) and 20 in the aortic region alone or in both regions (group A). The adjuvant therapy was administered as follows: subjects in group P received 50 Gy pelvic radiation, including three post-surgical T3 (pT3) patients who received either one or three cycles of cisplatin-based chemotherapy before radiation. Subjects in group A were given three cycles of chemotherapy followed by 50 Gy pelvic and 50 Gy extended field periaortic radiation using a four-field or conformational technique. Five-year survival was 95% for 143 patients with negative nodes and 84% for 30 patients with positive nodes (100% for group P and 75% for group A). In group A, 5-year survival was 38% for eight patients with both pT3 and histology other than endometrioid type Gl, and 91% for the remaining 12 patients. Either way, both group P and group A patients had a better prognosis than previously reported. In summary, aortic and pelvic lymphadenectomy and subsequent chemotherapy and radiation therapy based on node status seem to improve the survival of endometrial cancer patients with positive nodes.

show abstract

mentioning

confidence: 99%

Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy

Onda

Yoshikawa²,

Mizutani³

et al. 1997

Br J Cancer

164

View full text Add to dashboard Cite

show abstract

“…The response rate of these agents used as monotherapy has been reported as 24%–48% for doxorubicin and 21%–25% for cisplatin [565758596061]. Carboplatin has been reported to exhibit similar response rates of 17%–33% [626364]. Other drugs, paclitaxel, cyclophosphamide and topotecan, also showed a similar response rate of approximately 20% [5765666768].…”

Section: Clinical Considerations and Recommendationsmentioning

confidence: 99%

Practice guidelines for management of uterine corpus cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement

Lee

Hong

et al. 2017

J Gynecol Oncol

View full text Add to dashboard Cite

Clinical practice guidelines for gynecologic cancers have been developed by many organizations. Although these guidelines have much in common in terms of the practice of standard of care for uterine corpus cancer, practice guidelines that reflect the characteristics of patients and healthcare and insurance systems are needed for each country. The Korean Society of Gynecologic Oncology (KSGO) published the first edition of practice guidelines for gynecologic cancer treatment in late 2006; the second edition was released in July 2010 as an evidence-based recommendation. The Guidelines Revision Committee was established in 2015 and decided to produce the third edition of the guidelines as an advanced form based on evidence-based medicine, considering up-to-date clinical trials and abundant qualified Korean data. These guidelines cover screening, surgery, adjuvant treatment, and advanced and recurrent disease with respect to endometrial carcinoma and uterine sarcoma. The committee members and many gynecologic oncologists derived key questions from the discussion, and a number of relevant scientific literatures were reviewed in advance. Recommendations for each specific question were developed by the consensus conference, and they are summarized here, together with other details. The objective of these practice guidelines is to establish standard policies on issues in clinical areas related to the management of uterine corpus cancer based on the findings in published papers to date and the consensus of experts as a KSGO Consensus Statement.

show abstract

“…The most active classes of chemotherapy agents in metastatic endometrial cancer are anthracyclines, platinum compounds, and taxanes, all of which produce response rates of greater than 20% (Table 1). [30][31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48] Single Agent Dose Response Rate (%) Doxorubicin 30-32,43 50-60 mg/m 2 Q 3 wks 17-37 Epirubicin 33 80 mg/m 2 Q 3 wks 26 Cisplatin [39][40][41] 50-100 mg/m 2 Q 3-4 wks 17-42 Carboplatin [35][36][37][38] 360-400 mg/m 2 Q 4 wks 24-33 Paclitaxel [44][45][46][47][48] Various 20-36 Docetaxel 42 35 mg/m 2 per wk 21 Ifosfamide 34 5 g/m 2 Q 3 wks 12-25 Etoposide 42 50 mg/d × 21 days Q 4 wks 14 Anthracyclines have been most extensively studied, with doxorubicin and epirubicin having similar overall response rates between 17% and 37% [30][31][32][33][34]49 and median time to progression of 6 to 9.5 months. Interestingly, pegylated liposomal doxorubicin was shown to have a single-agent response rate of only 9.5%.…”

Section: Single-agent Chemotherapymentioning

confidence: 99%

“…34,[39][40][41]49,52 Carboplatin yields similar response rates to cisplatin with less toxicity. [34][35][36][37][38]49,52 Paclitaxel is the third drug that has consistently shown single-agent response rates of greater than 20%, in this case even when administered in patients with prior cytotoxic chemotherapy. 34,[44][45][46][47][48][49]52 No other drug has shown response rates this high in the second-line setting.…”

Section: Single-agent Chemotherapymentioning

confidence: 99%